Evidence map›Paper›PMID 38589745›Full record

ArticleUpdates in surgery2024

Evolution of transplant oncology indications: a single-institution experience over 40 years.

Quirino Lai, Simona Parisse, Stefano Ginanni Corradini, Flaminia Ferri, Konstantina Kolovou, Pasquale Campagna, Fabio Melandro, Gianluca Mennini, Manuela Merli, Massimo Rossi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Updates in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Quirino LaiGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy. lai.quirino@libero.it.ORCID http://orcid.org/0000-0003-1487-3235
Simona ParisseDepartment of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Stefano Ginanni CorradiniDepartment of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Flaminia FerriDepartment of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Konstantina KolovouGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Pasquale CampagnaGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Fabio MelandroGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Gianluca MenniniGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Manuela MerliDepartment of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.
Massimo RossiGeneral Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation (LT) for uncommon tumoral indications has changed across the decades, with impaired results reported in the first historical series mainly for non-tumoral-related causes. Recently, renewed interest in liver transplant oncology has been reported. The study aims to analyze a mono-center experience exploring the evolution and the impact on patient survival of LT in uncommon tumoral indications. A retrospective analysis of 851 LT performed during 1982-2023 was investigated. 33/851 (3.9%) uncommon tumoral indications were reported: hepatocellular carcinoma (HCC) on non-cirrhotic liver (n = 14), peri-hilar (phCCA) (n = 8) and intrahepatic cholangiocarcinoma (i-CCA) (n = 3), metastatic disease (n = 4), hepatic hemangioendothelioma (n = 2), and benign tumor (n = 2). Uncommon tumoral indications were mainly transplanted during the period 1982-1989, with a complete disappearance after the year 2000 and a slight rise in the last years. Poor outcomes were reported: 5-year survival rates were 28.6%, 25.0%, 0%, and 0% in the case of HCC on non-cirrhotic liver, phCCA, i-CCA, and metastases, respectively. However, the cause of patient death was often related to non-tumoral conditions. LT for uncommon oncological diseases has increased worldwide in recent decades. Historical series report poor survival outcomes despite more recent data showing promising results. Hence, the decision to transplant these patients should be under the risk and overall benefit of the patient. The results of the ongoing protocol studies are expected to confirm the validity of the unconventional tumor indications.

Indexed as

Carcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsLiver TransplantationAdultAgedBile Duct NeoplasmsFemaleHemangioendotheliomaHumansMaleMiddle AgedRetrospective StudiesSurvival RateTime FactorsTreatment OutcomeColorectal liver metastasesHemangioendotheliomaHepatocellular carcinomaIntra-hepatic cholangiocellular carcinomaPeri-hilar cholangiocellular carcinoma

Identifiers

PMID38589745
PMCPMC11130028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.